Haleon plc - ADR
HLN
Market Cap$47.26B
Close$
Earnings Call Q2 2024
August 2, 2024 - AI Summary
Haleon reported a 1% growth in North America for the first half of 2024, with Q2 showing a decline due to inventory reductions and proactive measures taken regarding phenylephrine products.
The company expects the net sales growth in North America to improve in the second half as inventory reductions and other changes are factored into the base.
Organic sales growth in the second half is expected to be at least at the upper end of the 4% to 6% range, driven by strong performance in oral health and VMS categories.
Exclusive for Stockcircle Pro members
Sign up
$8.03
18.1% downside
Current Fair Value
18.1% downsideOvervalued by 18.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.26 Billion |
|---|---|
| Enterprise Value | $55.30 Billion |
| Dividend Yield | $0.16 (2.00%) |
| Earnings per Share | $0.11 |
| Beta | 0.19 |
| Outstanding Shares | 9,178,758,595 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 66.63 |
|---|---|
| PEG | -0.85 |
| Price to Sales | 9.8 |
| Price to Book Ratio | 9.8 |
| Enterprise Value to Revenue | 4.92 |
| Enterprise Value to EBIT | 22.68 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
ESG Score
No data